Company Overview and News

25
PTLA / Portola Pharmaceuticals, Inc. PRE 14A

2018-04-13 sec.gov
ptla-pre14a_20180608.htm UNITED STATES
Upvote Downvote

 
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2018-04-04 globenewswire
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of Directors approved, effective as of March 30, 2018, the grant to four new employees of (i) inducement stock options to purchase an aggregate of 153,300 shares of common stock, including the grant of an inducement stock option to purchase 125,000 shares of common stock granted to John Moriarty, the Company’s newly appointed Executive Vice President and General Counsel, and (ii) awards of 39,150 restricted stock units in the aggregate, including an award to Mr.
Upvote Downvote

4
NHF: Objects In The Rear View Mirror Miss The Storms Ahead?

2018-03-27 seekingalpha
NHF is a closed-end fund sponsored by Highland Capital & NexPoint Advisors, primarily invested in below-investment-grade debt and equity with the ability to hedge risk.
Upvote Downvote

 
BRIEF-Portola Pharmaceuticals Plans To Appeal Negative CHMP Opinion For Betrixaban In The European Union

2018-03-23 reuters
* PORTOLA PHARMACEUTICALS RECEIVES AND PLANS TO APPEAL NEGATIVE CHMP OPINION REGARDING MARKETING AUTHORIZATION FOR BETRIXABAN IN THE EUROPEAN UNION
Upvote Downvote

 
EMA panel recommends against Portola's clot prevention drug

2018-03-23 channelnewsasia
A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.
Upvote Downvote

 
EMA panel recommends against Portola's clot prevention drug

2018-03-23 reuters
(Reuters) - A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc’s oral blood thinner, saying the benefits of the drug did not outweigh risks.
Upvote Downvote

 
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

2018-03-23 globenewswire
SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for betrixaban for the prevention of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death.
Upvote Downvote

1
BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study

2018-03-12 reuters
* PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXA® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING
Upvote Downvote

1
Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump

2018-03-12 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
Upvote Downvote

4
Portola Pharmaceuticals: What The Latest Developments Regarding AndexXA Entail?

2018-03-05 seekingalpha
Requisition by the FDA for additional data does not mean AndexXa won’t be approved in May this year.
Upvote Downvote

 
Portola: Elucidating The Latest Developments On Bevyxxa

2018-03-05 seekingalpha
As the first FDA-approved long-term VTE prevention, it is most likely that Bevyxxa will eventually generate blockbuster sales.
Upvote Downvote

2
Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125

2018-03-02 seekingalpha
Portola Pharmaceuticals (PTLA) shares have opened more than 25% lower amid speculation that the company’s AndexXa will require an additional trial before the FDA approves the BLA.
Upvote Downvote

2
U.S. Biotech/Pharma Sector Daily Observations Letter: March 1, 2018

2018-03-02 seekingalpha
We seem to be still in a consolidation phase after the runup in 2017. Treasury yield curve is flattening but another 'melt-up' seems likely to end this bull market in 2019. Around 23,925 on the Dow is a short-term support.
Upvote Downvote

1
PTLA / Portola Pharmaceuticals, Inc. 10-K (Annual Report)

2018-03-01 sec.gov
ptla-10k_20171231.htm UNITED STATES
Upvote Downvote

 
Portola Plunges After Hint of Delay for FDA Approval of Factor Xa-inhibitor

2018-03-01 biospace
Shares of Portola Pharmaceuticals have fallen more than 27 percent in early trading after the company announced a delay of several months for possible regulatory approval of is Factor Xa-inhibitor antidote, AndexXa.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 737010108